Prediction of the permeability of antineoplastic agents through nitrile medical gloves by zone classification based on their physicochemical properties.

Antineoplastic agents Medical gloves Molecular weight Nitrile Permeability Physicochemical properties Zone classification

Journal

Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177

Informations de publication

Date de publication:
02 Nov 2020
Historique:
received: 22 07 2020
accepted: 29 09 2020
entrez: 9 12 2020
pubmed: 10 12 2020
medline: 10 12 2020
Statut: epublish

Résumé

Permeability of antineoplastic agents through medical gloves is an important factor that must be considered for the appropriate selection of gloves. However, predicting the permeability of antineoplastic agents through medical gloves based on their physicochemical properties remains difficult. Thus, this study aimed to elucidate the relationship between the physicochemical properties and permeability of antineoplastic agents through medical gloves. Additionally, we tried to predict the risk of permeation of antineoplastic agents through medical gloves based on physicochemical parameters. Ten antineoplastic agents (carboplatin, carmustine, cisplatin, cyclophosphamide, doxorubicin, etoposide, fluorouracil, ifosfamide, oxaliplatin, and paclitaxel) with varying physicochemical properties were investigated, and their permeation rates (PRs) through nitrile medical gloves of varying thicknesses (0.05, 0.07, and 0.1 mm) were measured using a continuous flow in-line cell device. We also determined the apparent permeation clearance (CL The CL The permeation risk of antineoplastic agents through nitrile medical gloves within the actual continuous wearing time in clinical settings could be predicted using MW and LogP values. We believe that the proposed zone classification of antineoplastic agents will be a useful tool for predicting the permeation risk of antineoplastic agents through medical gloves.

Sections du résumé

BACKGROUND BACKGROUND
Permeability of antineoplastic agents through medical gloves is an important factor that must be considered for the appropriate selection of gloves. However, predicting the permeability of antineoplastic agents through medical gloves based on their physicochemical properties remains difficult. Thus, this study aimed to elucidate the relationship between the physicochemical properties and permeability of antineoplastic agents through medical gloves. Additionally, we tried to predict the risk of permeation of antineoplastic agents through medical gloves based on physicochemical parameters.
METHODS METHODS
Ten antineoplastic agents (carboplatin, carmustine, cisplatin, cyclophosphamide, doxorubicin, etoposide, fluorouracil, ifosfamide, oxaliplatin, and paclitaxel) with varying physicochemical properties were investigated, and their permeation rates (PRs) through nitrile medical gloves of varying thicknesses (0.05, 0.07, and 0.1 mm) were measured using a continuous flow in-line cell device. We also determined the apparent permeation clearance (CL
RESULTS RESULTS
The CL
CONCLUSIONS CONCLUSIONS
The permeation risk of antineoplastic agents through nitrile medical gloves within the actual continuous wearing time in clinical settings could be predicted using MW and LogP values. We believe that the proposed zone classification of antineoplastic agents will be a useful tool for predicting the permeation risk of antineoplastic agents through medical gloves.

Identifiants

pubmed: 33292621
doi: 10.1186/s40780-020-00179-3
pii: 10.1186/s40780-020-00179-3
pmc: PMC7604926
doi:

Types de publication

Journal Article

Langues

eng

Pagination

23

Références

Scand J Work Environ Health. 1980 Dec;6(4):299-301
pubmed: 7233118
J Occup Environ Hyg. 2020 Apr;17(4):172-180
pubmed: 32091311
J Pharm Health Care Sci. 2017 May 2;3:13
pubmed: 28469932
Mutat Res. 1999 Feb 2;439(1):97-104
pubmed: 10029685
Cancer Invest. 1986;4(2):127-35
pubmed: 3518876
Am J Health Syst Pharm. 2003 May 15;60(10):1006-11
pubmed: 12789871
J Occup Health. 2008;50(1):7-12
pubmed: 18285639
Am J Health Syst Pharm. 2014 Jan 15;71(2):145-66
pubmed: 24375608
Am J Health Syst Pharm. 2018 Dec 15;75(24):1996-2031
pubmed: 30327293
Mutat Res. 1985 Sep;154(2):135-49
pubmed: 3929080
Am J Health Syst Pharm. 2006 Mar 15;63(6):547-56
pubmed: 16522891

Auteurs

Toyohito Oriyama (T)

Tokyo University of Science, Faculty of Pharmaceutical Sciences, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan. oriyama-tky@umin.ac.jp.
Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. oriyama-tky@umin.ac.jp.

Takehito Yamamoto (T)

Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
The Education Center for Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Katsuhiko Nara (K)

Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Yohei Kawano (Y)

Tokyo University of Science, Faculty of Pharmaceutical Sciences, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan.

Katsuyoshi Nakajima (K)

Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hiroshi Suzuki (H)

Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Takao Aoyama (T)

Tokyo University of Science, Faculty of Pharmaceutical Sciences, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan.

Classifications MeSH